Startseite › Nichtkleinzelliges Lungenkarzinom › Indiana › Fort Wayne
Klinische Studien zu Nichtkleinzelliges Lungenkarzinom in Fort Wayne, IN
17 Studien zu Nichtkleinzelliges Lungenkarzinom suchen Teilnehmer an Standorten in und um Fort Wayne (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 2/3
- Parkview Research Center /ID# 277651, Fort Wayne
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Teilnehmer gesuchtPhase 1/2
- Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Parkview Regional Medical Center, Fort Wayne
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Teilnehmer gesuchtPhase 3
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Teilnehmer gesuchtPhase 3
- Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 2
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Teilnehmer gesuchtPhase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Teilnehmer gesuchtPhase 2/3
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Research Site, Fort Wayne
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Research Site, Fort Wayne
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Teilnehmer gesuchtPhase 1
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Teilnehmer gesuchtPhase 3
- Parkview Packnett Family Cancer Institute, Fort Wayne
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Teilnehmer gesuchtPhase 1
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
BostonGene and Exigent Genomic INsight Study
Teilnehmer gesuchtBeobachtungsstudie
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Nichtkleinzelliges Lungenkarzinom-Studien in anderen Städten
- Houston, TX145 Studien
- New York City, NY121 Studien
- Arlington, VA104 Studien
- Nashville, TN97 Studien
- Boston, MA90 Studien
- Los Angeles, CA87 Studien
- St. Louis, MO73 Studien
- Chicago, IL61 Studien
- Baltimore, MD60 Studien
- San Antonio, TX59 Studien
- Columbus, OH57 Studien
- Washington, DC55 Studien
Weitere Studien in Fort Wayne
- Eierstockkrebs8 Studien
- Krebs (alle Arten)7 Studien
- Chronische lymphatische Leukämie7 Studien
- Brustkrebs7 Studien
- Lungenkrebs6 Studien
- Metastasierender Krebs6 Studien
- Endometriumkarzinom5 Studien
- Melanom4 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich4 Studien
- Triple-negatives Mammakarzinom4 Studien
- Kolorektales Karzinom4 Studien
- Multiples Myelom4 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.